Evidence map›Paper›PMID 42062619›Full record

SynthesisCancer metastasis reviews2026

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.

Bálint Dér, Melinda Váradi, Nikolett Nagy, Andras Kubik, Gladell P Paner, Gopa Iyer, Nadine T Gaisa, Sara E Wobker, Richard Bambury, Bas W G van Rhijn and 4 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bálint DérDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary.
Melinda VáradiDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary.
Nikolett NagyDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary.
Andras KubikDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary.
Gladell P PanerDepartments of Pathology and Surgery, Section of Urology, University of Chicago, Chicago, IL, USA.
Gopa IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nadine T GaisaInstitute of Pathology, University Hospital RWTH Aachen, RWTH Aachen University, Aachen, Germany.
Sara E WobkerDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Richard BamburyMedical Oncology, Cork University Hospital, Cork, Ireland.
Bas W G van RhijnDepartment of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Hikmat Al-AhmadieDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Péter NyirádyDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary.
Henning ReisInstitute of Pathology, University of Duisburg-Essen, Essen, Germany.
Tibor SzarvasDepartment of Urology, Semmelweis University, Üllői Út 78/B. 1082, Budapest, Hungary. szarvas.tibor@semmelweis.hu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Innovációs és Technológiai Minisztérium K139059NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Adenocarcinomas are rare histological subtypes of bladder cancer mainly presenting as primary bladder adenocarcinomas (PBACs), or urachal carcinomas (UrCs). The lack of standardized, evidence-based clinical recommendations for therapy results in individualized treatment decisions. These personalized treatments may be tailored based on molecular analyses to target driver mutations. The genetic background of UrC and PBAC has been increasingly explored through molecular analysis of relatively small case series. Similarly, experiences with targeted treatments are available from individual case reports and single institution case series. Consequently, currently available genetic and targeted treatment data are fragmented, hindering a comprehensive overview and firm conclusions. Therefore, we aimed to catalogue and interpret recent molecular genetic insights and targeted therapeutic experiences in UrC and PBAC in order to provide a basis for improved clinical decision-making. In this review, we screened online databases with search terms selective for genetic and targeted therapeutic data in UrC and PBAC. Utilizing the extracted data, we identified mutational frequencies, created OncoPrints, investigated signaling pathways, and evaluated treatment approaches guided by precision medicine. Our summary of genetic findings and targeted therapy strategies are intended to support off-label options for UrC and PBAC.

Indexed as

AdenocarcinomaUrinary Bladder NeoplasmsGenomicsHumansMolecular Targeted TherapyMutationPrecision MedicineGeneticsPrecision medicinePrimary bladder adenocarcinomaTargeted therapyUrachal cancer

Identifiers

PMID42062619
PMCPMC13133215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.